<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00342940</url>
  </required_header>
  <id_info>
    <org_study_id>V78P4S</org_study_id>
    <secondary_id>Eudract number:2006-000787-88</secondary_id>
    <nct_id>NCT00342940</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older</brief_title>
  <official_title>A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, When Administered to Non-Elderly Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The present study aims to evaluate safety and immunogenicity of one dose of a commercially
      available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, in
      non-elderly adult and elderly subjects.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of Vaccine Supplies
  </why_stopped>
  <start_date>October 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CHMP criteria for evaluation of flu vaccines e.g Seroprotection, GMR's and Seroconversion rate at day 21 following vaccination</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with at least one local reaction between Day 0 and Day 3 after vaccine injection.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with at least one systemic reaction between Day 0 and Day 3 after vaccine injection.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with at least one adverse event between Day 0 and the study termination visit (Day 21, window: 20-24).</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Influenza</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>influenza surface antigen inactivated vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects 18 years of age or older

        Exclusion Criteria:

          -  any auto-immune disease or other serious acute, chronic or progressive disease

          -  hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,
             neomycin or polymyxin or any other component of the vaccine

          -  known or suspected (or high risk of developing) impairment/alteration of immune
             function

          -  within the past 7 days any acute disease or infections requiring systemic antibiotic
             or antiviral therapy

          -  history of neurological symptoms or signs, or anaphylactic shock following
             administration of any vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines Drug Information Services</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiltern International Limited , Chiltern Place, Upton Road</name>
      <address>
        <city>Slough</city>
        <zip>SL1 2AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2006</study_first_submitted>
  <study_first_submitted_qc>June 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2006</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <keyword>influenza</keyword>
  <keyword>influenza vaccine</keyword>
  <keyword>flu</keyword>
  <keyword>vaccination</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

